Miracell Expands Overseas Markets, Participating in the Paris Expo, After Visiting Italy and the Middle East
“Introducing the bio stem cell extraction system ‘Smart Mcell 2’ to the world!
[Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) is accelerating the export of its self-developed “Bio Stem Cell Extraction System.”
Miracell’s Smart Mcell 2, a system capable of selectively collecting large quantities of stem cells, received certification as a “New Health Technology” from the Ministry of Health and Welfare in February of last year. Capable of isolating and extracting approximately 2.9 billion cells per session in less than an hour, this cutting-edge bio-device, equipped with special LEDs to enhance cell activity, is being used for therapeutic purposes at major hospitals in Korea.
Miracell will be attending the “IMCAS World Congress 2022,” a medical device exhibition, held in Paris, France, from June 3rd to 5th, to connect with global buyers with the Smart Mcell 2.
To promote its bio-stem cell extraction system, “Smart M-Cell 2,” globally, Miracell participated in the International Medical Devices Fair 2022 in São Paulo, Brazil (May 17-20) and Cosmoprof Bologna 2022 in Italy (April 28-May 1),
receiving favorable reviews from the bio industry and healthcare professionals.
“Smart M-Cell 2” is also poised to enter the Middle East market.
CEO Shin Hyun-soon visited Jordan, Qatar, Kuwait, Saudi Arabia, and Dubai in April and May to negotiate contracts with buyers he met at the Dubai International Medical Devices Fair in January, and has achieved significant results with a series of contracts.
Miracell, through its membership in the Cellpia Global Platform (CGP), has built an organic network with medical professionals at domestic and international hospitals and clinics, sharing its specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing to hospitals both domestically and internationally, ensuring safe stem cell regenerative medicine treatments.
CEO Shin Hyun-soon stated, “Currently, Smart Mcell 2 has received European CE certification and is in the process of obtaining US FDA approval. We anticipate that this technology, which meets international standards, will enable us to conquer the global market.”